In a significant move, UK-based pharmaceutical giant GlaxoSmithKline (GSK) has sealed a three-year, £2.5 billion deal with Chongqing Zhifei Biological Products Co., aiming to fortify the presence of its shingles
Explore the company’s impact on the healthcare landscape, emphasizing its dedication to innovation and widespread vaccine availability